Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Henlius carves out $440M T-cell engager deal with Amberstone
Fosun Pharma subsidiary Henlius Biotech has signed a $440 million deal with California-based Amberstone Biosciences to work on T-cell engagers.
James Waldron
Sep 24, 2026 10:02am
Roche notches ph. 3 lung cancer win but trails GSK on survival
Sep 14, 2026 5:50am
GSK’s ADC lays down marker for lung cancer scrap with Merck
Sep 12, 2026 7:00pm
Tyra rolls toward pivotal cancer study even as stock deflates
Sep 9, 2026 9:30am
TScan axes 75% of staff to make room for solid tumor programs
Sep 2, 2026 10:46am
Roche drops lupus TCE, retains autoimmune cell therapy interest
Jul 23, 2026 4:51am
